Tony Berberabe

1 week ago | targetedonc.com | Tony Berberabe

Adding panitumumab (Vectibix) to neoadjuvant FOLFOX (folinic acid, fluorouracil, and oxaliplatin) chemotherapy reduced recurrence and improved survival in patients with locally advanced colon cancer (LACC) whose tumors lacked RAS or BRAF mutations, according to exploratory findings from the FOxTROT trial (ISRCTN838426).

2 weeks ago | targetedonc.com | Tony Berberabe

The anti-LAG-3 antibody LBL-007, combined with toripalimab, demonstrated a manageable safety profile and antitumor activity in patients with nasopharyngeal carcinoma (NPC) and other solid tumors, according to findings from a phase 1b/2 trial (NCT05102006). Investigators reported a confirmed objective response of 13.3% (95% CI, 6.6%-23.2%). The disease control rate was 54.7% (95% CI, 42.7%–66.2%).

2 weeks ago | cancernetwork.com | Tony Berberabe

Nogapendekin alfa inbakicept (NAI; Anktiva) elicited sustained complete response (CR) rates, progression-free survival (PFS), and high rates of cystectomy avoidance in patients with high-risk Bacillus Calmette-Guérin (BCG)-unresponsive bladder carcinoma in situ (CIS), with or without papillary disease, according to a 36-month analysis from cohorts A and B of the phase 2/3 QUILT-3.032 trial (NCT03022825) presented at the 2025 American Urological Association (AUA) Annual Meeting.1 In cohort A...

2 weeks ago | onclive.com | Tony Berberabe

The T-cell engaging bispecific antibody runimotamab plus trastuzumab (Herceptin) displayed promising efficacy vs runimotamab monotherapy for the treatment of patients with HER2-positive breast cancer, according to data from a phase 1 dose-escalation study (NCT03448042) during the 2025 AACR Annual Meeting.1 Findings from the study showed that the combination demonstrated an overall confirmed objective response rate (ORR) of 19% across all dose levels (n = 73) and an ORR of 30% at the 20 mg/60...

2 weeks ago | targetedonc.com | Tony Berberabe

The combination of runimotamab, a T-cell engaging bispecific antibody, and trastuzumab (Herceptin) resulted in encouraging clinical activity and improved tolerability compared with runimotamab monotherapy in patients with HER2-positive breast cancer, according to a phase 1 dose-escalation study (NCT03448042).1 Findings from the study presented at the 2025 AACR Annual Meeting showed that the combination achieved an overall confirmed objective response rate (ORR) of 19% across all dose levels...